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AbstrACt
Purpose Essential to exposome research is the collection 
of data on many environmental exposures from different 
domains in the same subjects. The aim of the Human 
Early Life Exposome (HELIX) study was to measure and 
describe multiple environmental exposures during early 
life (pregnancy and childhood) in a prospective cohort 
and associate these exposures with molecular omics 
signatures and child health outcomes. Here, we describe 
recruitment, measurements available and baseline data of 
the HELIX study populations.
Participants The HELIX study represents a collaborative 
project across six established and ongoing longitudinal 
population-based birth cohort studies in six European 
countries (France, Greece, Lithuania, Norway, Spain and 
the UK). HELIX used a multilevel study design with the 
entire study population totalling 31 472 mother-child pairs, 
recruited during pregnancy, in the six existing cohorts 
(first level); a subcohort of 1301 mother-child pairs where 
biomarkers, omics signatures and child health outcomes 
were measured at age 6–11 years (second level) and 
repeat-sampling panel studies with around 150 children 
and 150 pregnant women aimed at collecting personal 
exposure data (third level).
Findings to date Cohort data include urban environment, 
hazardous substances and lifestyle-related exposures for 
women during pregnancy and their offspring from birth 
until 6–11 years. Common, standardised protocols were 
used to collect biological samples, measure exposure 
biomarkers and omics signatures and assess child health 
across the six cohorts. Baseline data of the cohort show 
substantial variation in health outcomes and determinants 
between the six countries, for example, in family affluence 
levels, tobacco smoking, physical activity, dietary habits 
and prevalence of childhood obesity, asthma, allergies and 
attention deficit hyperactivity disorder.
Future plans HELIX study results will inform on the 
early life exposome and its association with molecular 
omics signatures and child health outcomes. Cohort data 
are accessible for future research involving researchers 
external to the project.
IntroduCtIon 
The ‘exposome’ concept encompasses 
the totality of non-genetic exposures from 
conception throughout the life course, 
complementing the genome.1 The expo-
some concept carries the expectation 
that the use of holistic and data-driven 
approaches, similar to those pioneered in 
the genomics fields, can result in advances 
in our understanding of the complex envi-
ronmental component of disease aeti-
ology. The exposome has been delineated 
to include three overlapping and comple-
mentary domains2: (1) a general external 
domain including macrolevel factors such 
as climate, urban environment and societal 
factors; (2) an individual external domain 
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including agents such as environmental pollutants, 
tobacco smoke, diet and physical activity and (3) a 
specific internal domain including gene expression, 
inflammation and metabolism, often assessed through 
high-throughput molecular omics methodologies such 
as transcriptomics, proteomics and metabolomics.
The HELIX project aims to measure and describe 
multiple environmental exposures from the different 
exposome domains during early life (pregnancy and 
childhood) and associate these with omics markers and 
child health outcomes. The background, rationale and 
detailed objectives of the HELIX project have been 
described elsewhere at the start of the project.3 HELIX 
takes early life as a key starting point for defining the 
exposome because, as recognised in the Develop-
mental Origins of Health and Disease research, it is 
well recognised that the periods of organ development 
during prenatal life and infancy are especially vulner-
able to the effects of environmental risk factors, which 
may manifest themselves throughout the lifetime in 
adult diseases.4 Essential to exposome research is the 
collection of data on many environmental exposures 
from the different exposome domains in the same 
subjects. Here, we describe recruitment, study popu-
lation, measurements available and baseline data of 
the HELIX nested study populations, with an aim to 
provide a detailed description of the cohort and of the 
data available for future collaborative research.
Cohorts PArtICIPAtIng In hELIX
The HELIX study represents a collaborative project 
across six established and ongoing longitudinal popu-
lation-based birth cohort studies in Europe: the Born in 
Bradford (BiB) study in the UK,5 the Étude des Détermi-
nants pré et postnatals du développement et de la santé 
de l’Enfant (EDEN) study in France,6 the INfancia y 
Medio Ambiente (INMA) cohort in Spain,7 the Kaunus 
cohort (KANC) in Lithuania,8 the Norwegian Mother 
and Child Cohort Study (MoBa)9 and the RHEA 
Mother Child Cohort study in Crete, Greece10 (table 1). 
These cohorts were selected for participation in the 
HELIX project because: (a) they could provide substan-
tial existing longitudinal data from early pregnancy 
through childhood, (b) they could follow-up children 
at similar ages, (c) they could integrate questionnaires, 
Table 1 Characteristics of the cohorts contributing to the HELIX cohort
Cohort Recruitment in original cohort
Exclusions made during 
recruitment Years of birth
Region covered 
by HELIX
No. of births in 
HELIX entire cohort
BiB, UK5 All pregnant women who attended 
the oral glucose tolerance test clinic 
at Bradford Royal Infirmary in weeks 
26–28 of pregnancy.
Women who planned to move 
away from Bradford before birth 
were excluded.
2007–2010 Bradford 10 849
EDEN, 
France6
Pregnant women who attended 
prenatal care at the University 
hospitals of Nancy and Poitiers 
recruited before 24 weeks of 
amenorrhoea.
Twin pregnancies, women with 
known diabetes before pregnancy, 
insufficient French language 
skills and intention to move away 
from the recruitment area were 
excluded.
2003–2006 Nancy and
Poitiers, urban 
areas
1900
INMA, 
Spain7
Pregnant women who attended a 
prenatal care centre in the study 
region during weeks 6–10 of 
pregnancy.
Women who resided or intended to 
deliver outside the study area, who 
were aged under 16 years, who 
had twin or multiple pregnancies, 
who had assisted reproduction or 
who had communication problems 
were excluded.
2003–2008 Gipuzkoa
Sabadell
Valencia
2063
KANC, 
Lithuania8
Pregnant women who attended one of 
four prenatal care clinics affiliated to 
the hospitals of the Kaunas University 
of Medicine during first trimester of 
pregnancy.
Women who lived outside 
Kaunas municipality, had medical 
records of pregnancy induced 
hypertension and/or diabetes were 
excluded.
2007–2008 Kaunas 4107
MoBa, 
Norway9
Recruitment at the first ultrasound 
(US) scan, ie, during the 17–18 weeks 
of gestation. All women who gave 
singleton births in the participating 
maternity units.
None 1999–2008 Oslo 11 095
RHEA, 
Greece10
Pregnant women who attended 
US examination before 15 week of 
pregnancy with residence in and near 
Heraklion at Crete.
Women who were aged under 
16 years or who had 
communication problems were 
excluded.
2007–2008 Heraklion 1458
Total 31 472
BiB, Born in Bradford; EDEN, Étude des Déterminants pré et postnatals du développement et de la santé de l’Enfant; INMA, INfancia y Medio 
Ambiente; KANC, Kaunus cohort; MoBa, Norwegian Mother and Child Cohort Study. 
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biosampling and clinical examinations using common 
HELIX protocols and (d) they offered heterogeneity in 
terms of exposure and population characteristics.
Pregnant women in the original cohorts were recruited 
between 1999 and 2010. Three cohorts (INMA, KANC, 
RHEA) recruited during the first trimester of pregnancy, 
two through the first and second trimesters (EDEN, 
MoBa), while in the BiB cohort women were recruited 
between weeks 26 and 28 of gestation (second/third 
trimesters). Inclusion and exclusion criteria varied 
between cohorts, as described in table 1. All cohorts 
included at least one follow-up point during pregnancy, 
one at birth and several after delivery.
Based on these six existing cohorts, HELIX used 
a multilevel study design, drawing on nested study 
populations for data collection of different inten-
sities (figure 1): (1) the entire cohort in which factors 
arising primarily from outdoor exposures were assessed 
through geospatial models and linked to existing 
health outcome data; (2) a subcohort in which one new 
follow-up examination of the children between ages 6 
and 11 years was carried out in order to assess child 
health outcomes and to fully characterise different 
areas of the exposome through questionnaires, biolog-
ical sample collection and biomarker and omics 
measurements and (3) two panel studies in children 
and pregnant women to characterise in depth the vari-
ability in exposure biomarkers and omics biomarkers, 
individual exposure-related behaviours and personal 
exposures.
Figure 1 Flow chart describing design and available data. GIS, Geographic Intelligent Software; HELIX, Human Early Life 
Exposome; miRNA, microRNA; mtDNA, mitochondrial DNA. *Omics data available after quality control 
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hELIX EntIrE Cohort
The study population for the entire HELIX cohort 
includes 31 472 women who had singleton deliveries 
between 1999 and 2010, and for whom exposure to 
ambient air pollution during pregnancy had been esti-
mated as part of the European Study of Cohorts for Air 
Pollution Effects (ESCAPE) project.11 The entire cohort 
includes nine regions from the six cohorts; we included 
only regions where geographic data were available to 
calculate air pollution levels and built environment indi-
cators (table 1). This meant, for example, that the city 
of Oslo and not the whole of the national MoBa cohort 
was included, and that only the Gipuzkoa, Sabadell and 
Valencia regions of the INMA study were included. In 
the other cohorts, women residing outside the main 
urban areas were excluded for the same reason.
In this study population, data on many variables had 
been collected in the individual cohorts during previous 
data collection points (during pregnancy and between 
birth and 5 years of age). Existing data included infor-
mation on certain exposures (eg, maternal tobacco 
smoking during pregnancy, environmental tobacco 
smoke), key covariates (eg, pregnancy complications, 
maternal and child diet, maternal and child physical 
activity, child sleep, breast feeding, other health-re-
lated behaviours, indicators of socioeconomic status) 
and health and development outcomes. As part of 
HELIX, relevant datasets from all 31 472 mother-child 
pairs were transferred from the six cohorts to the 
central HELIX data warehouse located at the Barce-
lona Institute for Global Health (ISGlobal) (see below). 
Through data harmonisation, these cohort-specific 
variables were converted to harmonised variables. This 
process involved summarising, checking and matching 
the specific variable cohort-by-cohort and deciding a 
common coding system appropriate to each variable. 
Specific expert working groups throughout the HELIX 
consortium advised on the harmonisation rules for each 
variable. The child health and developmental outcomes 
harmonised as part of HELIX include birth outcomes, 
growth-related and obesity-related outcomes, blood 
pressure, neurodevelopment and respiratory health 
between birth and 5 years of age (table 2).
hELIX subCohort
From the entire cohort, a subcohort of mother-child 
pairs was selected to be fully characterised for a broad 
Table 2 Health outcomes harmonised across the entire cohort between birth and 5 years of age
Health/development 
outcomes Methods BiB EDEN INMA KANC MoBa RHEA
Total number of 
subjects in the 
harmonised dataset
Birth
  Birth weight Measurements √ √ √ √ √ √ 31 472
  Gestational duration Medical records/
ultrasound
√ √ √ √ √ √ 31 472
0–5 years
  Repeated weight, height, 
BMI
Measurements and 
records
√ √ √ √ √ √ 28 305
  Waist circumference Measurements 
   1–2 years √ √ √ √ 4598
   4–5 years √ √ √ √ 4275
  Skinfolds Measurements 
   1–2 years √ √ √ 3364
   4–5 years √ √ √ 2774
  Blood pressure (4–5 years) Measurements √ √ √ √ 5182
  Cognition Psychologist-
administered tests and 
parental questionnaires
√ √ √ 3470
  Motor skills, language Psychologist-
administered tests and 
parental questionnaires
√ √ √ √ √ 10 245
  Behaviour Questionnaires √ √ √ √ √ √ 12 644
  Asthma, wheeze Questionnaires √ √ √ √ √ √ 12 068
  Lung function (4–5 years) Spirometry √ √ √ √ 2719
BiB, Born in Bradford; BMI, body mass index; EDEN, Étude des Déterminants pré et postnatals du développement et de la santé de l’Enfant; 
INMA, INfancia y Medio Ambiente; KANC, Kaunus cohort; MoBa, Norwegian Mother and Child Cohort Study. 
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suite of environmental exposures and ‘omics’ data, to 
be clinically examined and to have biological samples 
collected. A new follow-up visit was organised for 
these mother-child pairs between December 2013 and 
February 2016. Subcohort subjects were recruited from 
within the entire cohorts such that there were approx-
imately 200 mother-child pairs from each of the six 
cohorts. Subcohort recruitment in the EDEN cohort 
was restricted to the Poitiers area and in the INMA 
cohort to the city of Sabadell.
Eligibility criteria for inclusion in the subcohort were: 
(a) age 6–11 years at the time of the visit, with a prefer-
ence for ages 7–9 years if possible; (b) sufficient stored 
pregnancy blood and urine samples available for analysis 
of prenatal exposure biomarkers; (c) complete address 
history available from first to last follow-up point; (d) 
no serious health problems that may affect the perfor-
mance of the clinical testing or impact the volunteer's 
safety (eg, acute respiratory infection). In addition, 
the selection considered whether data on important 
covariates (diet, socioeconomic factors) were available. 
Each cohort selected participants at random from the 
eligible pool in the entire cohort and invited them to 
participate in this subcohort until the required number 
of participants was reached. In total, 1301 mother-child 
pairs with complete questionnaire and clinical examina-
tion data, and urine and blood samples, were included 
in the HELIX subcohort (figure 1).
Several cohorts then invited and examined further 
subjects (n=322) following the same protocols for clin-
ical examination and sample collection, and the same 
questionnaires, but these were not included in the 
measurement of exposure biomarkers for the HELIX 
study (figure 1). Among the 322 extra individuals, 266 
came from INMA-Sabadell, 26 from BiB, 7 from EDEN, 
3 from KANC, 19 from MoBa and 1 from RHEA. For 
some of these individuals omics data were collected. 
These individuals may be included in studies with 
another focus than exposure biomarkers, which is why 
they are shown in figure 1.
The new follow-up visits for the subcohort took place 
in the six study centres at a local hospital, a primary 
care centre or at the National Institute for Public 
Health (NIPH) in Oslo. During the follow-up examina-
tion, trained nurses interviewed the mothers, carried 
out health examinations of the children and collected 
biological samples using standardised operating 
procedures.
Questionnaire information
Interviews with the mothers during the visit used a 
computer-aided version of a common standardised ques-
tionnaire developed for HELIX. Questionnaires were 
translated and back-translated in each of the country 
languages. If it was not possible for the mother to attend 
(although the mother’s attendance was greatly encour-
aged on recruitment), then the father or legal guardian 
completed the questionnaire and the mother checked 
it at a later date at home. This happened for 4% of the 
children. The full questionnaire can be accessed online 
(https:// tinyurl. com/ yat9hao4).
The questionnaire collected information on child’s 
diet including an internationally agreed food frequency 
questionnaire with portion size examples appropriate 
to each cohort and the reliability of the Mediterra-
nean diet quality index questionnaires to assess Medi-
terranean diet,12 physical activity of the child, sleeping 
patterns of child, socioeconomic status (family affluence 
scale (FAS II),13 ie, subjective wealth), social capital of 
the family,14 stress of the mother,15 exposure to envi-
ronmental tobacco smoke, water consumption habits, 
cooking and heating methods at the home, cleaning 
products, bedroom location, noise perception, child's 
use of mobile phones and other electronic devices, use 
of green spaces, commuting behaviour, holidays and 
sun exposure and puberty development of the child.
Questions on exposures during the day and week 
before the visit were asked separately in a short ques-
tionnaire and repeated during the second period of 
nested child panel study (see below). Additionally, 
questions related to addresses, places visited and travel 
were collected using a custom-made Google maps-
aided commuting questionnaire based on the free 
Geographic Intelligent Software (GIS), qGIS software16 
that allowed mothers to trace their child’s commuting 
routes directly on the computer. This information was 
used to enhance the accuracy of location data collected 
through the main questionnaires and integrated with 
the outdoor exposure estimates to provide expo-
sure estimates at different locations and for different 
time-activity patterns (eg, home, school, commuting 
exposures). A total of 98.3% of mothers in the subco-
hort completed the qGIS commuting questionnaire.
Anthropometry and body composition
During the subcohort follow-up examination, anthro-
pometric data were collected using regularly calibrated 
instruments: height was measured with a stadiometer 
and weight with a digital weight scale, both without 
shoes and with light clothing. Height and weight 
measurements were converted to body mass index 
(BMI in kg/m²) for age-and-sex z-scores using the 
international WHO reference curves in order to allow 
comparison with other studies.17 Overweight and obese 
children were defined as those above the age-and-
sex-specific 85th and 95th percentiles, respectively, as 
recommended by WHO (http://www. who. int/ media-
centre/ factsheets/ fs311/ en/). Circumferences (arm, 
waist, head) were measured with a metric tape and 
recorded in duplicate.
Four skinfolds were measured (triceps, subscapular, 
suprailiac, thigh), following the protocols as described 
in the report from National Health and Nutrition 
Examination Survey III Body Measurements (anthro-
pometry).18 Three complete sets of each skinfold 
measurement were taken consecutively, and the mean 
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was used as the representative value for each site. A 
skinfold is the thickness of a double fold of skin and 
subcutaneous fat, excluding the underlying muscle. 
Skinfolds are highly correlated with total body fat and 
a way to assess the distribution of fat tissue. Specific 
training workshops (one before and one during field 
work) were organised to standardise skinfold and other 
anthropometric measurements between the cohorts. In 
these workshops, all field workers participated and were 
trained to obtain measurements that were comparable 
to those measured by an expert anthropometrist.
Bioelectric impedance analyses readings were 
performed with the Bodystat 1500 (Bodystat, Douglas, 
Isle of Man) equipment after 5 min of lying down. 
Bioelectric impedance provides an objective measure 
of body composition when standard protocols are 
followed and population-specific equations are avail-
able and used. Fat free mass and fat mass (in grams and 
as proportion of total body mass) were calculated based 
on values of impedance, using published age-specific 
and race-specific equations validated for use in chil-
dren.19 The multiracial equations developed recently 
for children based on impedance values obtained by 
a single frequency tetra-polar Bodystat device19 fit well 
the measures obtained from children in HELIX using 
the same device.
blood pressure
Blood pressure was taken in sitting position after 5 min 
of rest using the OMRON 705-CPII automated oscillo-
metric device. The mean of three consecutive measure-
ments that were taken with 1 min intervals was used.20 
Blood pressure was measured towards the end of the 
visit to ensure that children had not consumed anything 
that may affect the results (chocolate, cola drinks) in 
the previous hour. Systolic and diastolic blood pressures 
and pulse rate from each measurement were recorded.
respiratory health
Lung function measures were obtained through forced 
spirometry test, using the EasyOne spirometer in chil-
dren by trained field workers using a standardised 
protocol. During the measurements, the child was 
sitting straight and equipped with a nose clip and 
asked to breathe in as deeply possible until his/her 
lungs were totally full, and then to quickly position the 
mouthpiece and blast out the air as hard and as fast as 
possible. The child was asked to perform at least six of 
these manoeuvres to achieve the three acceptable and 
reproducible manoeuvres needed for a valid test. While 
acceptability and reproducibility criteria for spirometry 
have been well defined for adults, the criteria to be used 
for children lack clarity and consistency.21–23 Based on 
international standards,21 24 a manoeuvre was defined 
as acceptable if there was no hesitation of false starts 
(ie, if the back-extrapolated volume (BEV) was <5% 
of the forced vital capacity (FVC) or if BEV <100 mL 
if FVC <1000 mL) and if the forced expiratory time 
(FET) was in an acceptable range (1.5 s<FET<10 s). 
The highest values for forced expiratory volume at one 
second (FEV1) taken from acceptable forced expiratory 
manoeuvres should not vary >150 mL or 5% (or <100 mL 
if FVC <1000 mL) from the second highest FEV1. Then, 
the per cent predicted values FEV1 were computed 
using the Global Lung Initiative equations, and any best 
FEV1% predicted value in the (60%; 140%) range was 
retained. Following these criteria, 79.4% of the HELIX 
children performed a valid test.
Information on occurrence of wheeze, asthma, 
eczema, allergic rhinitis and food allergy in the chil-
dren was obtained through questions adapted from the 
International Study on Asthma and Allergy in Child-
hood by the Mechanisms of the Development of Allergy 
project (MeDALL).25
neurodevelopment
Neurodevelopmental outcomes were assessed through 
a battery of internationally standardised, non-linguistic, 
and culturally blind computer tests. The tests included 
N-back26 and the attention network test27 to assess 
working memory and sustained attention, the trail 
making test28 to assess speed of processing and executive 
functions, the finger tapping test to assess motor speed 
and lateralisation29 and Raven's coloured progressive 
matrices30 to assess general non-verbal intelligence. The 
tests were administered through standardised study-pro-
vided laptops and lasted a maximum of 1 hour. Rooms 
for testing were ensured to be quiet and the tests were 
done with minimal interference. Field workers were 
trained to instruct children in a standardised way.
A proxy of maternal IQ or cognitive functioning is an 
important cofactor to be assessed in any study where the 
neurodevelopment is the main outcome. The mothers 
(or father if the mother was not available) completed a 
short version of N-back (no more than 6 min) adapted 
to adults.
Parents completed the Conner rating scale’s and 
child behaviour checklist (CBCL) before the visit to 
assess child behavioural problems. The Conner rating 
scale’s of 27 items provides information on child 
behaviour, particularly in relation to inattention and 
hyperactivity.31 CBCL is one of the most recognised and 
extended tools to fully assess a child behavioural func-
tioning and contains several subscales, including aggres-
sive behaviour, anxiety/depression, attention problems, 
internalising problems, externalising problems, etc.32
biological sample collection
During the subcohort follow-up examination, new 
biological samples suitable for all planned exposure 
biomarker and omics analyses were collected using 
the same standardised protocols across all six cohorts 
as shown in figure 1. Two spot urine samples (one 
before bedtime and one first morning void) were 
collected in high-quality polypropylene tubes (Sarstedt: 
75.9922.744). The two urine samples were brought by 
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the participants to the centre in cool packs and stored 
at −4°C until processing. After aliquoting, the urine 
samples were frozen at −80°C under optimised and 
standardised procedures. If the families did not bring 
urine samples with them, a new sample was collected on 
arrival at the centre. This occurred in 6.6% of the subco-
hort children; 18 mL of blood was collected during the 
follow-up visit at the end of the clinical examination 
of the child to ensure an approximate 3 hour (median 
3.5 hours, SD 1.1 hour) fasting time since the last meal. 
Blood samples were collected using a ‘butterfly’ vacuum 
clip and local anaesthetic and processed into a variety 
of sample matrices. It included EDTA Vacutainers 
designed for trace element testing, used for plasma 
proteomics, microRNA (miRNA) and perfluorinated 
alkylated substance analyses, blood smears, whole blood 
heavy metal and DNA isolation (BD: 368381, K2EDTA 
coated), tempus tubes for RNA isolation (Life Technol-
ogies Cat. No.: 4342792), plastic silica Vacutainers for 
serum metabolomics and clinical parameter analyses 
(BD: 3 68 813 silica coated, clot activator), glass silica 
Vacutainer for serum polychlorinated biphenyl, dichlo-
rodiphenyldichloroethylene, hexachlorobenzene, poly-
brominated diphenyl ether analyses (BD: 367614, silica 
coated, no activator). After processing, these samples 
were frozen at −80°C under optimised and standardised 
procedures. After performing the relevant assays, blood 
and urine samples, hair samples, RNA and DNA samples 
remain in storage for the subcohort children.
EXPosurE AssEssmEnt
To construct the exposome, HELIX has estimated expo-
sure to a wide range of environmental contaminant 
exposures and indicators of the built environment. In 
the entire cohort and subcohort, a GIS environment 
for the nine study areas was constructed, and, based on 
residential address histories, exposure estimates were 
assigned for ambient air pollutants, road traffic noise 
levels, surrounding (natural spaces green and blue 
spaces), built environment, ultraviolet (UV) radiation 
and meteorological variables during pregnancy and 
childhood (table 3). These estimates build on existing 
land-use regression air pollution models (ESCAPE 
project33 34), city noise maps, land use maps (‘Urban 
Atlas’ by European Environmental Protection Agency), 
raster maps of the normalised difference vegetation 
index (NDVI),35 36 raster maps of land surface tempera-
ture, building density, population density, connectivity, 
walkability and public bus transport map information 
for the built environment and meteorological data, 
as described in more detail elsewhere (Robinson 
and colleagues37). Data from existing regulatory moni-
tors were used to back extrapolate ambient air pollu-
tion exposure models. The estimates for these outdoor 
exposures were calculated for the prenatal period and 
several postnatal periods up to the HELIX subcohort 
follow-up time point (table 3).
Furthermore, in the subcohort, biomarkers of 
contaminant exposure were measured in appropriate 
biological samples collected from the children at age 
6–11 years and in samples previously collected from 
mothers during pregnancy or from the neonates during 
delivery (cord blood) and stored in cohort biobanks 
(table 3). Chemical assays were conducted in the labo-
ratory at the Department of Environmental Exposure 
and Epidemiology at the NIPH, apart from analyses of 
metals/elements and cotinine, creatinine and blood 
lipids, which were subcontracted to ALS Laboratory 
Group Norway AS and Dr Fürst Medisinsk Laboratorium 
AS, respectively. Biomarkers include: organochlorine 
compounds and brominated compounds, perfluoro-
alkyl substances and metals in blood, and non-per-
sistent chemicals (phthalate metabolites, phenols, 
organophosphate pesticide metabolites and cotinine) 
in urine samples (table 3). Concentrations of OCs and 
PBDEs were adjusted for to total lipid percentage and 
expressed in ng/g of lipids. Urinary concentrations 
were adjusted for creatinine and expressed in μg/g of 
creatinine. Urine samples of the night before the visit 
and the first morning void on the day of the visit were 
combined to provide a slightly long-term exposure 
assessment than can be achieved with one spot urine 
sample (Haug et al, s).
Concentrations of drinking water disinfection 
by-products (DBPs) during pregnancy were estimated 
from water company concentration and distribution 
data as part of the water contaminants and stillbirth, 
congenital anomalies, birth weight, preterm delivery 
(HiWate) project in four of the cohorts (BiB, KANC, 
INMA, RHEA).38 For EDEN and MoBa, we followed 
the same methodology to obtain estimates during preg-
nancy. Data were not sufficiently complete to estimate 
child exposure to DBPs. Indoor air concentrations of 
nitrogen dioxide (NO2), particulate matter <2.5 μm 
(PM2.5), particulate matter absorbance, benzene and 
toluene, ethylbenzene, xylene were estimated by 
combining measurements in the homes of a subgroup 
of children during the two periods of the nested panel 
studies (see below) with questionnaire data from the 
subcohort.
mEAsurEmEnt oF moLECuLAr sIgnAturEs
In the subcohort, we also obtained the following 
measurements of molecular omics signatures at the age 
of 6–11 years: blood leucocyte DNA methylation (450K, 
Illumina), whole blood transcription (HTA V.2.0, Affy-
metrix and SurePrint Human miRNA rel 21, Agilent), 
serum metabolites (AbsoluteIDQ p180 kit, Biocrates), 
urine metabolites (proton nuclear magnetic reso-
nance (1H NMR) spectroscopy) and plasma proteins 
(Luminex, cytokines 30-plex, apoliprotein 5-plex and 
adipokine 15-plex). Among the samples available for 
omics analyses, some were excluded because of the 
absence of genetic analysis consent (n=1), because the 
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Table 3 Exposure estimates available in the HELIX entire cohort and subcohort
Exposure group Description*
Pregnancy
(and specific 
trimesters)*
Postnatal
0–5 years
Subcohort
6–11 years
Outdoor and urban exposure estimates available in the entire cohort and in the subcohort
  Atmospheric pollutants NO2, PM2.5, PM10, PM2.5 (absorbance ratio) √ * √ √
  Ultraviolet (UV) Ambient UV radiation levels √ √ √
  Surrounding natural 
space
Average normalised difference vegetation index within 
buffers of 100, 300 and 500 m
Size of and distance to nearest major green or blue 
space (>5000 m2)
Presence of a major green or blue space in a distance 
of 300 m
√ √ √
  Meteorology Land surface temperature average in a buffer of 50 m
Temperature from meteorological stations (mean, 
minimum and maximum)
Humidity percentage from meteorological stations
Atmospheric pressure data from the ESCAPE project
√ * √ √
  Built environment Population density: inhabitants per km2
Building density: built area in m2 per km2 within 100 and 
300 m buffers
Street connectivity: number of road intersections per 
km2 within 100 and 300 m buffers
Accessibility: metres of bus public transport lines and 
number of bus public transport stops per km2 within 
100, 300 and 500 m buffers
Facilities: facility richness index and facility density 
index in a 300 m buffer
Land use evenness index
Walkability index in 300 m buffer*
√ √ √
  Traffic Total traffic load of major roads in a 100 m buffer, total 
traffic load in a 100 m buffer, traffic density on nearest 
road and inverse distance to nearest road
√ √ √
  Road traffic noise Day and night time road noise levels √ √ √
Contaminant exposure estimates available in the HELIX subcohort
  Organochlorine 
compounds
Blood concentrations of 
dichlorodiphenyldichloroethylene, 
dichlorodiphenyltrichloroethane, hexachlorobenzene 
and polychlorinated biphenyl—118, 68, 153, 170, 180. 
With and without lipid adjustment.
√ – √
  Brominated 
compounds
Blood concentrations of polybrominated diphenyl 
ether—47, 153. With and without lipid adjustment.
√ – √
  Perfluorinated 
alkylated substances
Blood concentrations of perfluorooctanoate, 
perfluorononanoate, perfluoroundecanoate, 
perfluorohexane sulfonate, perfluorooctane sulfonate
√ – √
  Metals and essential 
elements
Whole blood concentrations of arsenic, cadmium, 
cesium, cobalt, copper, lead, manganese, mercury, 
molybdenum, thallium, potassium, magnesium, sodium, 
selenium and zinc
√ – √
  Phthalate metabolites Urine concentrations of monoethyl phthalate, mono-
iso-butyl phthalate, mono-n-butyl phthalate, mono 
benzyl phthalate, mono-2-ethylhexyl phthalate, mono-
2-ethyl-5-hydroxyhexyl phthalate, mono-2-ethyl-5-
oxohexyl phthalate, mono-2-ethyl 5-carboxypentyl 
phthalate, mono-4-methyl-7-hydroxyoctyl phthalate, 
mono-4-methyl-7-oxooctyl phthalate. With and without 
creatinine adjustment.
√ – √
Continued
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blood DNA/RNA extraction failed (n=386, 22.8%, for 
RNA; n=22, 1.5%, for DNA), because omics data were of 
low quality (n=10 for transcriptomics), because of tech-
nical outliers (serum haemolysed, n=1), or because of 
failed sample identity checks for the methylome (n=4 
based on sex mismatch, and n=6 based on genotype 
mismatch between longitudinal HELIX samples from 
the same child or from existing genome-wide genetic 
data of the child). Telomere length and mitochondrial 
DNA content were measured by quantitative PCR as 
part of a separate project. Genome-wide genotyping 
will be completed as part of a separate project using the 
Infinium Global Screening Array from Illumina.
The number of omics markers varies greatly across 
the omics platforms: from 36 for proteomics to 480 071 
for the methylome (table 4). The platforms and data 
processing procedures selected for the proteins and 
serum metabolome were in fact targeted assays (<200 
Table 4 Omics features available in the HELIX subcohort and repeat child panel study
Omics Sample Platform Features
Subcohort 
(n=1300)*
Second period 
child panel study
Proteomics Plasma Luminex kits: cytokines 30-
plex, apoliprotein 5-plex and 
adipokine 15-plex
36 1170 154
Methylation Buffy coat 450K, Illumina 386 518 1173 153
Transcriptomics Whole blood HTA V.2.0, Affymetrix 35 841 1010 127
MicroRNA (miRNA) Whole blood SurePrint Human miRNA rel 21, 
Agilent
330 941 123
Urinary metabolomics Urine 1H NMR spectroscopy 44 1198 153
Serum metabolomics Serum AbsoluteIDQ p180 kit, Biocrates 177 1198 154
Telomere length
Mitochondrial DNA content
Buffy coat Quantitative real-time PCR 2 1166 153
*One child’s parents in the subcohort did not give genetic consent, therefore this child was excluded from all omics analyses.
HELIX,  Human Early Life Exposome. 
Exposure group Description*
Pregnancy
(and specific 
trimesters)*
Postnatal
0–5 years
Subcohort
6–11 years
  Phenols Urine concentrations of methyl paraben, ethyl paraben 
, bisphenol A, propyl paraben, N-butyl paraben, 
oxybenzone, triclosan. With and without creatinine 
adjustment.
√ – √
  Organophosphate 
pesticide metabolites
Urine concentrations of dimethyl phosphate, 
dimethyl thiophosphate, dimethyl dithiophosphate, 
diethyl phosphate, diethyl thiophosphate, diethyl 
dithiophosphate. With and without creatinine 
adjustment.
√ – √
  Tobacco smoking Urine levels of cotinine. Questionnaire on active and 
passive smoking.
√ – √
  Water disinfection by-
products
Total concentration of total trihalomethanes (THMs), 
chloroform and total brominated THMs estimated in 
tap water from water company concentration and 
distribution data.
√ – – 
  Indoor air Prediction models for indoor air concentrations of 
NO2, PM2.5, PMabs, benzene and toluene, ethylbenzene, 
xylene using panel study data from indoor air samplers.
– – √
*Walkability indicator adapted from the previous walkability indexes45 46: calculated as the mean of the deciles of population density, street 
connectivity, facility richness index and land use Shannon's Evenness Index within 300 m buffers, giving a walkability score ranging from 0 to 
1.
ESCAPE, European Study of Cohorts for Air Pollution Effects; HELIX, Human Early Life Exposome; NO2, nitrogen dioxide; PM2.5, mass 
concentration of particles <2.5 µm in aerodynamical diameter; PM10, mass concentration of particles <10 µm in aerodynamical diameter; 
PMabs, absorbance of PM2.5 filters; a proxy for elemental carbon, which is the dominant light absorbing substance.
Table 3 Continued 
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features) in order to obtain the best quality data for a 
large number of samples with fully annotated proteins 
and metabolites.39 Further data filtering was applied to 
decrease the apparent complexity in the omics data. 
For example, in the urine metabolome, generated from 
untargeted NMR spectroscopic analysis from 128K 
spectral data points, 44 metabolite integrals were calcu-
lated only for resonances with high abundance and 
limited overlap with other metabolite signals. Urine 
metabolites were normalised using the median fold 
change.40 Proteins were filtered out if 30% of samples 
were outside of the linear range of quantification. After 
an initial quality control, the number of CpGs, tran-
script clusters and miRNAs were: 480 071, 67 528 and 
2549, respectively. Additional filtering (ie, probes in 
sexual chromosomes, cross-hybridisation probes, etc) 
might be applied during data analysis.
Within the HELIX subcohort of 1301 mother-child 
pairs, we obtained the following final numbers of chil-
dren with omics data: n=941 for miRNA, 1010 for tran-
scripts, 1170 for proteins, 1173 for methylation and 
1198 for urine and serum metabolites; a total of 874 
children (67% of the subcohort) had complete expo-
sure and omics data (table 4, figure 1). Among these 
children, between 123 and 154, depending on the omic 
platform, also had a sample analysed for the second visit 
approximately 6 months later (table 4).
PAnEL studIEs
Intensive repeat panel studies collected data on short-
term temporal variability in exposure biomarkers and 
omics biomarkers, individual behaviours (physical 
activity, mobility) and personal and indoor exposures 
Table 5 Measurements performed in the child and pregnancy panel studies
Measurement
No. of subjects 
in child panel 
study*
No. of subjects 
in pregnancy 
panel study* Description
Measurement point/
period
Geolocation and mobility 146 126 Smartphone GPS with ExpoApp 
application installed
7 days in each study period
Physical activity 145 148 Smartphone and Actigraph 
accelerometer
7 days in each study period
NO2 154 158 Passive samplers for NO2 
installed in the home
7 days in each study period
BTEX 154 158 Passive samplers for BTEX 
installed in the home
7 days in each study period
PM2.5 92 90 Active PM2.5 Cyclone pumps 
(BGI-400–4), carried by 
participants in backpack and 
installed in the home
Last 24 hours of each of the 
two study periods
Black carbon 89 66 MicroAthelometer (AE51) for 
continuous monitoring
Last 24 hours of each of the 
two study periods
UV 69 141 Electronic wrist band UV 
dosimeters47
7 days in each study period
Phthalates, phenols, 
organophosphate 
pesticides
152 – Pool of bedtime and first 
morning urine
4 separate days in one 
study period
Phthalates, phenols, 
organophosphate 
pesticides, cotinine
152 154 Pool of daily urine samples (2 or 
3 per day) during 1 week
One pool in each of the two 
study periods
Phthalates – 44 All morning and bed time urines 
during 1 week
7 days in one study period
1H  NMR metabolomics 22 – All morning and bed time urines 
during 1 week
7 days in one study period
Lung function 62 – Spirometry Last day of period 1 and 2
Blood pressure 157 154 OMRON 705-CPII automated 
oscillometric device
Last day of period 1 and 2
Height and weight 157 145 Last day of period 1 and 2
*With data in both periods. 
BTEX, benzene, toluene, ethylene and meta-xylene, para-xylene and ortho-xylene; 1H NMR, proton nuclear magnetic resonance; NO2, 
nitrogen dioxide; PM 2.5, mass concentration of particles <2.5  µm in aerodynamical diameter; UV, ultraviolet. 
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(table 5). The child panel study included children from 
the HELIX subcohort (n=157, from all cohorts except 
MoBa) who lived in a first floor apartment or private 
house and were sampled following a maximum varia-
tion sampling strategy to high traffic-density exposure 
at home address. The pregnancy panel study included 
pregnant women from outside the cohorts in three 
cities, Barcelona, Grenoble and Oslo (n=154). The 
inclusion criteria for these pregnant women were to 
be 18 years or older at the start of pregnancy, to have 
a singleton pregnancy, to be living in the study area 
until delivery and to have the first visit before the end 
of gestational week 20. Participants in the child panel 
study were followed for 1 week in two seasons, whereas 
in the pregnancy panel study the participants were 
followed for 1 week in two trimesters. In the child panel, 
the last day of the first week coincided with the subco-
hort examination, detailed above.
Participants carried smartphones for measurement 
of physical activity and to collect geolocalisation data 
through the ExpoApp, a smartphone-based applica-
tion41 specifically developed for the project (table 5). 
Indoor air pollution exposure to NO2 and to vola-
tile organic compounds benzene, toluene, ethylben-
zene, meta-xylene, para-xylene and ortho-xylene, was 
measured through passive samplers installed in the 
homes. For the last 24 hours of the panel study periods, 
participants carried backpacks containing Active PM2.5 
Cyclone pumps and black carbon MicroAthelometer 
monitors (Model AE51, AethLabs, California, USA). 
Electronic wrist bands measured UV exposure (Scien-
terra, New Zealand).
Urine samples were collected twice daily (first 
morning void and bedtime sample) in the child panel 
study and three times per day (morning, afternoon, bed 
time) in the pregnancy panel. Urine samples were used 
to measure repeat biomarkers for non-persistent expo-
sures (phthalates, phenols, organophosphate pesticides 
and cotinine) and they were used to assess the variance 
in NMR metabolomics measured in the first morning 
void, bedtime and pooled urine42.
At the end of each monitoring week, blood samples 
were collected following the same procedures as for 
the subcohort, indeed the collection in week 1 was part 
of subcohort examination. Blood samples in the child 
panel study were also used to measure repeat omics 
signals (table 4). Lung function, blood pressure and 
anthropometric data were measured at the end of the 
panel study week following the same protocol as the 
subcohort clinical examination.
PAtIEnt And PubLIC InvoLvEmEnt
There was no patient involvement in this study. The six 
cohorts participating in the HELIX project recruited 
healthy pregnant mothers and followed their children 
up to 6–11 years. The cohort studies kept the families 
involved throughout these years through regular clinical 
and questionnaire follow-ups and disseminated study 
results to them through newsletters, family meetings 
and open days. The results are also regularly dissemi-
nated to local, national and international stakeholders.
FIndIngs to dAtE
baseline characteristics of the entire cohort
Main characteristics of the entire cohort are shown in 
table 6. Fifty-one per cent of the children in the entire 
cohort are boys; the average birth weight was 3372 g 
and the average gestational age 39.7 weeks; maternal 
age at delivery was 29.6 years on average; the majority 
of participants were from the highest educational level 
(51.6%); maternal BMI at the beginning of pregnancy 
showed a high percentage of overweight (25.6%) or 
mothers with obesity (15.8%) and 12.1% of mothers 
smoked during the entire pregnancy.
baseline characteristics of the subcohort
Basic characteristics of the subcohort were some-
what different to those of the entire cohort, probably 
reflecting selective participation of families in the 
intensive subcohort follow-up visit and data complete-
ness requirements (table 6). Compared with the entire 
cohort, the subcohort contained a greater percentage 
of boys, fewer children whose parents were born abroad 
(in particular in INMA and RHEA), a lower percentage 
of mothers with low education (in particular in BiB), 
a lower percentage of primiparous mothers (mainly in 
MoBa) and older mothers. The higher percentage of 
active smoking observed in the subcohort compared 
with the entire cohort was due to the fact that there 
were less missing values for smoking in the subcohort.
The age of the children in the subcohort at the time 
of the examination was 8.1 years on average, and this 
varied substantially between cohorts with the youngest 
ages being observed in KANC, RHEA and BiB (median 
age 6.4, 6.5 and 6.6 years, respectively), followed by 
MoBa and INMA (8.4 and 8.8 years, respectively), 
and the oldest ages in EDEN (11.0 years) (table 7). 
On average, 45.4% of the subcohort participants were 
girls, ranging from 42.9% in EDEN to 47.8% in MoBa. 
Most of the subcohort children were of white European 
origin, although the subcohort within BiB comprised 
43% white British and 44.9% of South Asian origin 
families with 12.1% of other ethnicities. The family’s 
economic situation as measured by the family affluence 
scale, showed marked differences between the cohorts 
with the majority of families in EDEN (78%), MoBa 
(72%) and INMA (54%) scoring high affluence, while 
lower affluence scores were observed in BiB, KANC 
and RHEA with 29.3%, 32.7% and 33.7% in the highest 
affluence category in those cohorts, respectively. The 
percentage of children classified with low family afflu-
ence was highest in BiB with 27.8%, while only around 
1% of children in EDEN and MoBa were from low 
family affluence.
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Maternal smoking during pregnancy was most prev-
alent in INMA (24.7%), EDEN (23.7%) and RHEA 
(21.2%) (table 7). Mothers’ replies to questions on 
environmental tobacco smoke exposure of the child 
showed that 34% of the children were exposed to envi-
ronmental tobacco smoke in at least one place (outdoor 
or indoor), ranging from 19% in MoBa to 69% in 
RHEA. Consumption of fruits was highest in BiB and 
MoBa, and of vegetables in EDEN and MoBa. Visits to 
fast food restaurants/takeaways were most frequent in 
BiB. Physical activity levels were constructed based on 
a self-reported questionnaire where we asked about the 
frequency, intensity and duration of performing phys-
ical activities at school, out of school, during weekends 
and during summer. Over-reporting and abnormal data 
were corrected based on predictive models built from 
the panel population accelerometer (Actigraph) data. 
Estimates in minutes per day of moderate to vigorous 
activity, that is, activities with intensity above three 
metabolic equivalents, were low in EDEN (17 min) 
and INMA (26 min) and high in KANC (42 min), BiB 
(42 min) and RHEA (49 min).
Food allergy questionnaires showed that overall 21% of 
children were reported to have at least one food allergy 
(ever experienced), ranging from 15.6% in RHEA to 
35% in INMA (table 7, figure 2). The percentage of chil-
dren who had ever had asthma was low in INMA (3.6%) 
and high in BiB (18.5%) and EDEN (20.2%). Overall, 
18.8% of children were overweight and 9.9% were obese 
(total 27.7%). The percentage of overweight and obese 
Table 6 Comparison of basic characteristics between the HELIX entire cohort (n=31 472), the subcohort (n=1301) and the 
child panel study (n=157)
Entire cohort Subcohort Panel study*
(n=31 472) (n=1301) (n=157)
Child characteristics
  Sex (%)
   Male 51.2 54.7† 56.1
   Female 48.8 45.4† 43.9
  Birth weight, g (SD) 3372 (547) 3379 (508) 3346 (479)
  Gestational age, weeks (SD) 39.7 (1.8) 39.6 (1.7) 39.5 (1.6)
Family characteristics
  Maternal age, years (SD) 29.6 (5.2) 30.8 (4.9)† 31.0 (4.9)‡
  Maternal education (%)
   Low 22.7 6.8† 6.8
   Middle 25.7 34.5† 34.5
   High 51.6 51.8† 51.8
  Maternal BMI* (%)
   Underweight/normal weight 58.6 60.9 58.1
   Overweight 25.6 24.4 25.8
   Obesity 15.8 14.7 16.1
  Country of origin of parents (%)
   Both from other country 21 11.1† 5.2‡
   One parent from other country 6.3 7.5† 4.5‡
   Both parents from country of cohort 65.7 81.4† 90.3‡
  Parity (%)
   0 previous pregnancies 50.7 45.9† 42.4
   ≥1 previous pregnancies 49.3 54.1† 57.6
  Maternal smoking during pregnancy (%)
   No 87.9 83.1† 85.3
   Yes 12.1 14.8† 14.7
*BMI grouped according to WHO categories for underweight (<18.5 kg/m2), normal (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2) and obese 
(≥30 kg/m2).
†P<0.05 comparing the subcohort (n=1301) with the entire cohort.
‡P<0.10 comparing the child panel study with non-panel subcohort children in the same cohorts (excluding MoBa).
HELIX, Human Early Life Exposome; MoBa, Norwegian Mother and Child  Cohort Study.
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children (using the age-and-sex-standardised z-scores) 
was highest in RHEA (37.2%) and INMA (42.3%) and 
lowest in MoBa (15.8%) (table 7, figure 2).
ADHD symptoms assessed through the Conner’s 
rating scale were classified using the cut-off score of 
the 80th percentile.42 Using this classification, 10.1% 
of children in the subcohort were classified as having 
ADHD symptoms, ranging from 4.4% in MoBa to 15.2% 
in KANC (table 7, figure 2). The total problems score 
of the CBCL, which consists of the sum of ratings on 
all 120 behavioural and emotional items of the CBCL, 
also showed that mothers in MoBa reported the lowest 
total score (median score 9) and mothers in KANC the 
highest (median score 27).
baseline characteristics of the child panel study
Participants in the child panel study (n=157, 28 from 
BiB, 28 from EDEN, 42 from INMA, 29 from KANC and 
30 from RHEA) were similar to the HELIX non-panel 
subcohort children of the same cohorts in terms of 
sociodemographic characteristics (table 6). The panel 
study included children whose mothers had similar ages, 
weight status and education than children not included 
in the panel. Birth weights and gestational ages were 
also similar between panel and non-panel children.
Through the child panel study, we showed that the 
pooled urine sample (before bedtime and first morning 
void) provided more coverage of the stable metabolome 
than would be achieved with either morning or bedtime 
urine sample alone.43 Through the repeated analysis of 
non-persistent exposures, we provided variability indi-
cators for each chemicals that can be used to correct 
dose-response relations and optimise sampling designs 
in future biomonitoring and exposome studies, and 
thus limit exposure misclassification (Casas, manuscript 
under revision).
strengths and limitations
The HELIX project has constructed a unique large 
exposome cohort, which included the prospective 
collection of objective data from different sources 
(biomonitoring data, geospatial data, sensor data, child 
health outcomes and omics signatures). These data can 
facilitate cross-validation of repeated information across 
different sources (eg, tobacco exposure estimated from 
questionnaire and cotinine biomarker) and the use of 
standardised tools and objective measures can allow 
international comparisons with other studies. The 
pluridisciplinary aspect of the HELIX study means that 
a wide range of environmental factors were measured 
including detailed information of socioeconomic 
factors, which will help unravelling the influences of 
pregnancy risk factors, the chemical and physical envi-
ronment, early family life and that of the school-age 
exposures on child development. Weaknesses include 
the loss to follow-up over time, a typical issue in most 
Figure 2 Prevalence of children with food allergy, asthma, overweight/obesity and ADHD symptoms in the HELIX subcohort 
at 6–11 years. BiB, Born in Bradford; EDEN, Étude des Déterminants pré et postnatals du développement et de la santé de 
l’Enfant; HELIX, Human Early Life Exposome; INMA, INfancia y Medio Ambiente; KANC, Kaunus cohort; MoBa, Norwegian 
Mother and Child Cohort Study; zBMI , age standardized z-score for body mass index . 
 o
n
 9 January 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-021311 on 10 September 2018. Downloaded from 
15Maitre L, et al. BMJ Open 2018;8:e021311. doi:10.1136/bmjopen-2017-021311
Open access
prospective longitudinal studies and lack of statistical 
power to study rare outcomes. Our sample size does 
not allow the investigation of rare diseases or extreme 
values for continuous traits unless data are pooled with 
those of other cohorts. In addition, those living outside 
urban areas were not included in the study due to the 
lack of outdoor environment data.
EthICs And dAtA ProtECtIon
Prior to the start of HELIX, all six cohorts on which 
HELIX is based had been in existence for some years, 
had undergone the required evaluation by national 
ethics committees and had obtained all the required 
permissions for their cohort recruitment and follow-up 
visits. Each cohort also confirmed that relevant informed 
consent and approval were in place for secondary use 
of data from pre-existing data. The work in HELIX was 
covered by new ethics approvals in each country, and at 
enrolment in the HELIX subcohort and panel studies 
participants were asked to sign an informed consent 
form for the specific HELIX work including clinical 
examination and biospecimen collection and analysis. 
An Ethics Task Force was established to support the 
HELIX project on ethical issues, for advice on the proj-
ect’s ethical compliance, identification and alerting to 
changes in legislation where applicable.
Specific procedures are in place within HELIX to 
safeguard the privacy of study subjects and confiden-
tiality of data. First, any reported study results pertain 
to analyses of aggregate data; no variables or combina-
tion of variables that can identify an individual will be 
associated with any published or unpublished report 
of this study. Primary databases with personal informa-
tion (such as geocodes, dates, questionnaires or health 
outcomes) have been stored on separate computers 
with personal identifiers removed. Subjects are identi-
fied by a unique study number, linking all basic data 
required for the study. The master key file linking the 
study numbers with personal identifiers is maintained 
in each cohort. For the dataset analysis, all informa-
tion that enables identification of an individual (dates, 
geocodes, etc) is removed before distribution of data-
sets to the researchers. All data exchanges will adhere 
to the most up-to-date EU and national data protection 
regulations.
dAtA wArEhousE
Relevant datasets from all 31 472 mother-child pairs 
were transferred from the six cohorts to the central 
HELIX data warehouse located at ISGlobal. The HELIX 
data warehouse consists of several schemas, which are 
linked by means of common identifiers in a relational 
database created in MySQL.44 New data, collected 
through the common protocols during the subcohort 
and panel study fieldwork, were entered directly into 
an electronic database and then uploaded into the data 
warehouse. Questionnaires were computer-based with a 
direct entry to the database. All data were locally and 
centrally checked by examination of the ranges, distri-
butions, means, SD, outliers and logical checks. Data 
outliers and missing values were checked with the local 
cohort field workers and, where possible and relevant, 
replaced by correct values. All new measurements of 
exposure biomarkers and omics from the labs, and all 
exposure variables estimated through geospatial models 
and other methods, were added to the data warehouse 
as they became available.
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